fig1
![Cardiomyocyte senescence and the potential therapeutic role of senolytics in the heart](https://image.oaes.cc/319bf9ae-eb6e-4cbd-81e4-47931a70823b/jca4006.fig.1.jpg)
Figure 1. Cardiomyocyte senescence. Upstream stressors such as aging, ischemia, ischemia/reperfusion, and doxorubicin activate the DNA damage response/p53 and p16 signaling, which in turn leads to cardiomyocyte senescence. Senescent cardiomyocytes feature enlarged cell size, increased levels of p16, p21, and γH2AX, increased senescence-associated β-galactosidase (SA-β-gal) activity, and the senescence-associated secretory phenotype (SASP). The accumulation of senescent cardiomyocytes in the heart results in cardiac hypertrophy, fibrosis, and dysfunction. The figure was generated with BioRender.com.